Reported Earlier, Gilead Sciences Announces $1.675B Acquisition Of Ouro Medicines With Up To $500M Milestones To Expand T Cell Engager Autoimmune Disease Portfolio
Gilead Sciences, Inc. -2.19%
Gilead Sciences, Inc. GILD | 132.89 | -2.19% |
Reported Earlier, Gilead Sciences Announces $1.675B Acquisition Of Ouro Medicines With Up To $500M Milestones To Expand T Cell Engager Autoimmune Disease Portfolio
